 HIV-1
"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 9 | 4 | 13 | | 1997 | 5 | 1 | 6 | | 1998 | 13 | 2 | 15 | | 1999 | 10 | 0 | 10 | | 2000 | 13 | 4 | 17 | | 2001 | 7 | 3 | 10 | | 2002 | 11 | 5 | 16 | | 2003 | 8 | 4 | 12 | | 2004 | 12 | 8 | 20 | | 2005 | 12 | 7 | 19 | | 2006 | 18 | 1 | 19 | | 2007 | 12 | 3 | 15 | | 2008 | 14 | 8 | 22 | | 2009 | 10 | 3 | 13 | | 2010 | 19 | 4 | 23 | | 2011 | 23 | 7 | 30 | | 2012 | 19 | 8 | 27 | | 2013 | 16 | 5 | 21 | | 2014 | 27 | 12 | 39 | | 2015 | 16 | 7 | 23 | | 2016 | 22 | 9 | 31 | | 2017 | 14 | 14 | 28 | | 2018 | 18 | 7 | 25 | | 2019 | 14 | 5 | 19 | | 2020 | 13 | 9 | 22 | | 2021 | 11 | 6 | 17 | | 2022 | 19 | 1 | 20 | | 2023 | 12 | 0 | 12 | | 2024 | 11 | 4 | 15 | | 2025 | 14 | 4 | 18 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Mann BT, Sanz M, Chitrakar A, Langlands K, Siegel M, Soriano-Sarabia N. Ex vivo-expanded allogeneic Vd2 T cells specifically reduce reservoirs of HIV-1 following latency reversal. JCI Insight. 2026 Mar 23; 11(6).
-
Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).
-
Ollerton MT, Folkvord JM, Bush V, Parry DA, Meditz AL, McCarter MD, Yost F, Shikuma CM, Connick E. Lymphoid B cells upregulate HIV-1 ex vivo and are linked to its expression in vivo. PLoS Pathog. 2025 Dec; 21(12):e1013661.
-
Rogg L, Underwood M, Hanan N, Castillo-Mancilla JR, Kahl L, Halliday F, Ghita GL, Jeffrey JL, Byrne S, Onodera T, Horton J, Gartland M. Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2025 Oct 06; 81(3):510-520.
-
Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.
-
Scallon AJ, Maheria P, Oyaro P, Thomas KK, Chohan BH, Odhiambo F, Brown E, Ochomo E, Karauki E, Yongo N, Hassan SA, Bishop MD, Beck IA, Boyce C, Frenkel LM, Abuogi L, Patel RC. Clinical, Psychosocial, and Structural Factors Associated with the Detection of HIV Drug Resistance in Children Living with HIV in Kisumu, Kenya: Secondary Analysis of Data from the Opt4Kids Study. Viruses. 2025 Sep 16; 17(9).
-
Parikh UM, Kudrick LD, Levy L, Bosek E, Chohan BH, Mukui I, Masyuko S, Ndlovu N, Mahaka I, Mugurungi O, Ncube G, Hettema A, Matse SN, Mullick S, Wallis CL, Heaps AL, Penrose KJ, McCormick KD, Wiesner L, Anderson PL, Peterson JM, Celum C, Richardson BA, Castor D, Allen S, Torjesen K, Mellors JW. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025 Aug; 28(8):e70011.
-
Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin E, Duff MO, Seese A, Marini-Macouzet C, Ballweber-Fleming L, Lee WH, Cottrell CA, Liguori A, Georgeson E, Alavi N, Kubitz M, Phelps N, Seaton KE, Cohen KW, Anderson MA, Mondal K, Laufer DS, Kublin JG, Ward AB, Hyrien O, De Rosa SC, Himansu S, Leav B, Reuter C, Tomaras GD, Montefiori D, Walsh SR, Frank I, Sobieszczyk ME, Goepfert PA, Stephenson KE, Baden LR, Van Tieu H, Keefer MC, Clark J, Riddler SA, Schief WR, McElrath MJ. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci Transl Med. 2025 Jul 30; 17(809):eady6831.
-
Panja S, Zaman LA, Zhang C, Patel M, Gorantla S, Dash PK, Gendelman HE. Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV-1 Proviral DNA Excision. Adv Healthc Mater. 2025 Sep; 14(25):e2501190.
-
Mann BT, Sanz M, Clohosey ML, Langlands K, Chitrakar A, Moreno-Soriano C, Vitalle J, Iannone MA, Ruiz-Mateos E, Deleage C, Siegel M, Soriano-Sarabia N. Dual role of circulating and mucosal Vd1 T cells in the control of and contribution to persistent HIV-1 infection. Nat Commun. 2025 Jul 01; 16(1):5817.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|